Somatotroph comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
== History == Occurrence of iron-containing red protein in bovine milk was reported as early as in 1939; however, the protein could not be properly characterized because it could not be extracted with sufficient purity. Its first detailed studies were reported around 1960. They documented the molecular weight, isoelectric point, optical absorption spectra and presence of two iron atoms per protein molecule. The protein was extracted from milk, contained iron and was structurally and chemically similar to serum transferrin. Therefore, it was named lactoferrin in 1961, though the name lactotransferrin was used in some earlier publications, and later studies demonstrated that the protein is not restricted to milk. The antibacterial action of lactoferrin was also documented in 1961, and was associated with its ability to bind iron. Recombinant lactoferrin production began in the 1990s with the expression of human lactoferrin (hLF) in microbial hosts, notably filamentous fungi such as Aspergillus oryzae, achieving yields exceeding 2 g/L in some cases. Yeast expression systems, particularly Pichia pastoris, were subsequently developed for scalable and cost-effective production. In a landmark development, Sydney-based biotechnology company All G became the first in the world to gain regulatory approval to sell recombinant bovine lactoferrin in China, achieved in November 2024 through precision fermentation (animal-free, microbe-based production).
Lance Forman (born October 1962); politician and businessman, who was a Member of the European Parliament (MEP) for London between 2 July 2019 and the United Kingdom's withdrawal from the EU; affiliated with Conservative Party, Forman was elected to the European Parliament as Brexit Party MEP; author of Forman's Games: The Dark Underside of the London Olympics and journalist for The Jewish Chronicle, The Telegraph, Daily Express, Metro (UK), The Spectator. Giles Fraser (born 27 November 1964) English Anglican priest of Jewish ancestry, journalist and broadcaster; regular contributor to Thought for the Day and The Guardian and a panellist on The Moral Maze, as well as an assistant editor of UnHerd; voted Stonewall Hero of the Year in 2012; lectures on moral leadership for the British Army at Defence Academy. Jonathan Freedland, journalist and leading liberal Zionist; worked on kibbutz in Israel with the Labour Zionist Habonim Dror (where Freedland had been a mentor to Sacha Baron Cohen); later writing for The Guardian, Daily Mirror, the London Evening Standard, The Jewish Chronicle, The New York Times, The New York Review of Books, Newsweek and The New Republic; in 2022 wrote highly acclaimed stage play Jews. In Their Own Words which the Royal Court Theatre described as a "searing and incisive play looking at the roots and damning legacy of antisemitism in Britain"; son of biographer and journalist Michael Freedland, and Israeli-born Sara Hocherman. He also writes fiction under the pseudonym Sam Bourne.
== History == The founding meeting for the CSCC was held in Montreal, Quebec on October 17, 1956. Since that time, the membership has grown to several hundred clinical chemists. In 1986 the Canadian Academy of Clinical Biochemistry was established as the academic body of the CSCC to oversee training, certification, accreditation, and professional development of clinical chemists in Canada. A syllabus for post doctoral training in clinical biochemistry was developed and is maintained by the CACB as a guide to program directors and trainees. The CSCC holds an Annual Scientific Congress and Annual General Meeting. The 61st annual CSCC conference was held in San Diego, CA, USA from July 31-August 4, 2017 as a joint meeting with the AACC.
Other approaches ("metabolism-first" hypotheses) focus on how catalysis on the early Earth might have provided the precursor molecules for self-replication. The 1952 Miller–Urey experiment demonstrated that amino acids can be synthesized from inorganic compounds under conditions like early Earth's. Subsequently, amino acids have been found in meteorites, comets, asteroids, and star-forming regions of space. While the last universal common ancestor of all modern organisms (LUCA) existed millions of years after the origin of life, its study can guide research into early universal characteristics. A genomics approach has sought to characterize LUCA by identifying the genes shared by Archaea and Bacteria, major branches of life. It appears there are 60 proteins common to all life and 355 prokaryotic genes that trace to LUCA; their functions imply that LUCA was anaerobic with the Wood–Ljungdahl pathway, deriving energy by chemiosmosis, and used DNA, the genetic code, and ribosomes. Earlier cells might have had a leaky membrane and been powered by a naturally occurring proton gradient near a deep-sea white smoker hydrothermal vent; or, life may have originated inside the continental crust or in water at Earth's surface. Although Earth is the only place known to harbor life, astrobiologists assume that life exists and came into being by similar processes on other planets. Geochemical and fossil evidence informs most studies. The Earth was formed at 4.54 Gya, and the earliest evidence of life on Earth dates from 3.8 Gya from Western Australia.
Sources: en.wikipedia.org
== Spectrum of Activity == Oritavancin is active against gram-positive aerobic bacteria such as enterococci, staphylococci, streptococci, and anaerobic bacteria such as Clostridioides difficile, Clostridium perfringens, Peptostreptococcus spp., and Cutibacterium acnes. Oritavancin's spectrum of activity shows similarities to vancomycin, but with lower minimum inhibitory concentrations (MIC).
One product of fatty acid metabolism are the prostaglandins, compounds having diverse hormone-like effects in animals. Prostaglandins have been found in almost every tissue in humans and other animals. They are enzymatically derived from arachidonic acid, a 20-carbon polyunsaturated fatty acid. Every prostaglandin therefore contains 20 carbon atoms, including a 5-carbon ring. They are a subclass of eicosanoids and form the prostanoid class of fatty acid derivatives. The prostaglandins are synthesized in the cell membrane by the cleavage of arachidonate from the phospholipids that make up the membrane. This is catalyzed either by phospholipase A2 acting directly on a membrane phospholipid, or by a lipase acting on DAG (diacyl-glycerol). The arachidonate is then acted upon by the cyclooxygenase component of prostaglandin synthase. This forms a cyclopentane ring roughly in the middle of the fatty acid chain. The reaction also adds 4 oxygen atoms derived from two molecules of O2. The resulting molecule is prostaglandin G2, which is converted by the hydroperoxidase component of the enzyme complex into prostaglandin H2. This highly unstable compound is rapidly transformed into other prostaglandins, prostacyclin and thromboxanes. These are then released into the interstitial fluids surrounding the cells that have manufactured the eicosanoid hormone. If arachidonate is acted upon by a lipoxygenase instead of cyclooxygenase, hydroxyeicosatetraenoic acids and leukotrienes are formed. They also act as local hormones.
=== Theatres, auditoriums and concerts === There are two main cultural axes in Le Havre: the central city and the Eure district. The Espace Oscar Niemeyer consists of a part of the "Great Volcano", a national theatre seating 1,093 (which houses the National Choreographic Centre of Le Havre Haute-Normandie directed by Hervé Robbe) and secondly the "Little Volcano" with a 250-seat multi-purpose hall for live performances. The whole Espace Oscar Niemeyer has been worked on since 2011: the little volcano will be transformed into a multimedia library. As for the performances at the Great Volcano, they are now taking place in the old ferry terminal until the end of construction. Other cultural institutions of the city centre are being transformed: the cinema of art and a trial of Le Sirius facing the university will reopen in 2013. Le Tetris at the fort of Tourneville will, in 2013, be a place devoted to contemporary music. Other cultural venues are scattered in the city centre: the cinema Le Studio, the theatre of the City Hall (700 seats), the Little Theatre (450 seats), the Théâtre des Bains Douches (94 seats), Akté theatre (60 seats), and the Poulailler (Henhouse)) (associative theatre with 50 seats) host numerous shows each year. The National Choreographic Centre of Le Havre Haute-Normandie specialises in the creation and production of dance shows. Other shows and performances are given in other places and at the Conservatory Arthur Honegger. The second cultural centre of the city is in the Eure district near the Basin Vauban.
== Discoveries made using egg extracts == Purification of M-phase promoting factor (MPF) Elucidation of the role of synthesis and degradation of cyclin B in cell cycle progression Discovery that degradation of a protein(s) other than cyclin B is necessary for initiating chromosome segregation Discovery of a mechanism of spindle assembly that depends on chromatin, but not centrosomes Proposal of a DNA replication licensing system and identification of its responsible factor Identification of importin α/β responsible for nuclear transport Discovery of the condensin complex essential for mitotic chromosome assembly Identification of the cohesin complex essential for sister chromatid cohesion More recently, the egg extracts have been used to study reprogramming of differentiated nuclei, physical properties of spindles and nuclei, and theoretical understanding of cell cycle control.
Moxonidine (INN) is an imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. It may have a role when thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or have failed to control blood pressure. In addition, it demonstrates favourable effects on parameters of the insulin resistance syndrome, apparently independent of blood pressure reduction. It is also a growth hormone releaser. It is manufactured by Solvay Pharmaceuticals (acquired by Abbott in 2009) under the brand name Physiotens and Moxon.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.